InterMune Inc. said Monday the Food and Drug Administration granted the biotechnology company’s developing lung condition drug pirfenidone priority review. Pirfenidone is aimed at the chronic lung disease idiopathic pulmonary fibrosis, which affects about…

Email this Article
Add to del.icio.us
Add to digg
Add to Facebook




Food and Drug Administration – Disease – Health – Diseases & Conditions – Interstitial lung disease

More here:
InterMune lung drug gets FDA priority review